



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 34 Y

Referral Testing

Collected: 05/22/2020 13:11

Received: 05/22/2020 13:11

Test Name	Result	Flag	Ref-Ranges	Units	Site
c-KIT Mutation Analysis, Cell Based					
c-KIT Specimen Source	Whole Blood				QCRL
Paraffin Block #	20-123456				QCRL
C-KIT Mutation, Cell-based	DETECTED	AB			QCRL

Reference Range:
NOT DETECTED

Activating c-kit mutations have been identified in various human cancers. The mutations are not detected in normal individuals. C-kit exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate. C-kit exon 9, 11, 13, 17 mutations have been reported in 90% GIST patients. The presence of a mutation usually predicts poor survival. C-kit exon 17 mutation has been reported in patients with systemic mastocytosis.

Except for D816V mutation, most other mutations are believed to be sensitive to Gleevec therapy.

The sensitivity of this sequencing assay is 20% of mutant cell in the background of normal cells.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at:
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92690-6130 I Maramica MD, PhD, MBA

Reported Date: 05/22/2020 13:12 CKMAC

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

B322000002
WX0000003039
Printed D&T: 11/30/23 10:41

Ordered By: CLIENT CLIENT
WX00000000001595

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1